Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT02638701
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Infliximab — DRUG
    Please see protocol for details.

Study Details

Patients harboring dolichoectactic vertebrobasilar (DVB) aneurysms are at risk of suffering SAH, ischemic stroke, and/or brainstem compression and many patients are not offered invasive treatment due to the futility of existing surgical methods. Consequently, there is demand for development of medical therapy for DVB aneurysms

Key Dates

Start date
Oct 1, 2024
Status verified
Jun 2026
Primary completion
Jun 30, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
8 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Infliximab treatment
    Administer infliximab intravenously to patients with DVB aneurysms (3 mg/kg at 0, 3 and 7 weeks, then at 8-week intervals x 7) for a total of 12-months. Patients will undergo MR imaging at 0, 12, and 24-month time points.

Primary Outcome Measure

Reduction in aneurysm volume (ml) [ Time Frame: 12 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UCSF Medical CenterSan FranciscoCalifornia94143
Daniel L Cooke, MD
[email protected]
415-353-1863
Atakan Orscelik, MD
[email protected]
415-353-7500

Find similar trials in San Francisco, CA

By condition
Stroke
By specialty
NeurologyBrain disorders
By research site
UCSF Medical Center· San Francisco, CA

Related Studies